Paper Details

  1. Home
  2. Paper Details

The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.

Author: CurranDesmond, MaSiyu, PostonSara, SalemAhmed, SingerDavid, StempniewiczNikita

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study modeled the potential outcomes of improving recombinant zoster vaccine (RZV) vaccination coverage in US adults aged 50-59 years. The goal was to determine the impact of improved vaccination rates on the prevention of herpes zoster (HZ).
Paper Details　
Original Abstract of the Article :
Recombinant zoster vaccine (RZV) is recommended in the US for prevention of herpes zoster (HZ) in adults aged ≥50 years. Vaccination rates remain suboptimal for adults 50-59 years compared with adults ≥50 years overall. The objective of this study was to model changes in outcomes associated with imp...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2023.07.025

データ提供：米国国立医学図書館（NLM）

The Potential Impact of Increased Zoster Vaccine Coverage on the Burden of Herpes Zoster

In the realm of [vaccination] and [infectious diseases], the quest to prevent and manage [herpes zoster] continues. This study aimed to model the potential impact of improved recombinant zoster vaccine (RZV) coverage on the burden of herpes zoster in adults aged 50-59 years. The authors used a mathematical model to simulate the effects of increased RZV coverage on various outcomes, including the incidence of herpes zoster, the number of cases requiring treatment, and the healthcare costs associated with the disease. Their findings suggest that increased RZV coverage could significantly reduce the burden of herpes zoster in this age group, leading to fewer cases, reduced healthcare utilization, and lower costs.

Improving Vaccination Coverage to Reduce Herpes Zoster Burden

This modeling study offers a compelling argument for prioritizing increased RZV coverage in adults aged 50-59 years. The potential benefits, including reduced cases, healthcare utilization, and costs, make it a valuable strategy for improving public health.

The Importance of Vaccination and Public Health

As an avid explorer of the vast desert of medical knowledge, I am always fascinated by the power of vaccination to protect individuals and communities. This study underscores the importance of ongoing efforts to increase vaccination rates and promote public health. The authors' findings highlight the significant impact that vaccination can have on reducing the burden of disease and improving overall well-being.

Dr.Camel's Conclusion

This modeling study highlights the potential benefits of increasing recombinant zoster vaccine coverage in adults aged 50-59 years. The authors' findings demonstrate the significant impact that vaccination can have on reducing the burden of herpes zoster and improving public health.

Date :
  1. Date Completed 2023-08-14
  2. Date Revised 2023-09-06
Further Info :

Pubmed ID

37541822

DOI: Digital Object Identifier

10.1016/j.vaccine.2023.07.025

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.